Viral Genetics, Inc. (OTC BB: VRAL), a drug development company developing a biological therapy for the treatment of HIV infection, stated on March 31, 2006 that it expected no significant delay in the release of the results of the clinical trial conducted in South Africa. The Company reiterates this expectation and it is continuing to analyze the data, which is now unblinded. Given the relative size of the database and the importance of the study, the Company is taking extra diligence in its analysis to ensure that it is properly interpreted and communicated to the public and all stakeholders.
